162 related articles for article (PubMed ID: 28928461)
41. Renal glucose handling: impact of chronic kidney disease and sodium-glucose cotransporter 2 inhibition in patients with type 2 diabetes.
Ferrannini E; Veltkamp SA; Smulders RA; Kadokura T
Diabetes Care; 2013 May; 36(5):1260-5. PubMed ID: 23359360
[TBL] [Abstract][Full Text] [Related]
42. A Lower Baseline Urinary Glucose Excretion Predicts a Better Response to the Sodium Glucose Cotransporter 2 Inhibitor.
Hwang YC; Kim JH; Lee BW; Lee WJ
Diabetes Metab J; 2019 Dec; 43(6):898-905. PubMed ID: 31237132
[TBL] [Abstract][Full Text] [Related]
43. Prevention of progression of diabetic nephropathy by the SGLT2 inhibitor ipragliflozin in uninephrectomized type 2 diabetic mice.
Tahara A; Takasu T
Eur J Pharmacol; 2018 Jul; 830():68-75. PubMed ID: 29702076
[TBL] [Abstract][Full Text] [Related]
44. Unmasking a sustained negative effect of SGLT2 inhibition on body fluid volume in the rat.
Masuda T; Watanabe Y; Fukuda K; Watanabe M; Onishi A; Ohara K; Imai T; Koepsell H; Muto S; Vallon V; Nagata D
Am J Physiol Renal Physiol; 2018 Sep; 315(3):F653-F664. PubMed ID: 29790389
[TBL] [Abstract][Full Text] [Related]
45. Discovery of Ipragliflozin (ASP1941): a novel C-glucoside with benzothiophene structure as a potent and selective sodium glucose co-transporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes mellitus.
Imamura M; Nakanishi K; Suzuki T; Ikegai K; Shiraki R; Ogiyama T; Murakami T; Kurosaki E; Noda A; Kobayashi Y; Yokota M; Koide T; Kosakai K; Ohkura Y; Takeuchi M; Tomiyama H; Ohta M
Bioorg Med Chem; 2012 May; 20(10):3263-79. PubMed ID: 22507206
[TBL] [Abstract][Full Text] [Related]
46. SGLT2 inhibitor and loop diuretic induce different vasopressin and fluid homeostatic responses in nondiabetic rats.
Masuda T; Ohara K; Vallon V; Nagata D
Am J Physiol Renal Physiol; 2022 Sep; 323(3):F361-F369. PubMed ID: 35900341
[TBL] [Abstract][Full Text] [Related]
47. Atypical Ketoacidosis and Protracted Hyperglycosuria after Treatment with Ipragliflozin, an SGLT2 Inhibitor.
Miyauchi M; Toyoda M; Fukagawa M
Intern Med; 2017; 56(13):1673-1678. PubMed ID: 28674356
[TBL] [Abstract][Full Text] [Related]
48. Efficacy and safety of sodium-glucose cotransporter 2 inhibitor ipragliflozin on glycemic control and cardiovascular parameters in Japanese patients with type 2 diabetes mellitus; Fukuoka Study of Ipragliflozin (FUSION).
Nomiyama T; Shimono D; Horikawa T; Fujimura Y; Ohsako T; Terawaki Y; Fukuda T; Motonaga R; Tanabe M; Yanase T;
Endocr J; 2018 Aug; 65(8):859-867. PubMed ID: 29806620
[TBL] [Abstract][Full Text] [Related]
49. Ipragliflozin, an SGLT2 Inhibitor, Ameliorates High-Fat Diet-Induced Metabolic Changes by Upregulating Energy Expenditure through Activation of the AMPK/ SIRT1 Pathway.
Lee JY; Lee M; Lee JY; Bae J; Shin E; Lee YH; Lee BW; Kang ES; Cha BS
Diabetes Metab J; 2021 Nov; 45(6):921-932. PubMed ID: 33611885
[TBL] [Abstract][Full Text] [Related]
50. Characterization and comparison of sodium-glucose cotransporter 2 inhibitors: Part 2. Antidiabetic effects in type 2 diabetic mice.
Tahara A; Takasu T; Yokono M; Imamura M; Kurosaki E
J Pharmacol Sci; 2016 Jul; 131(3):198-208. PubMed ID: 27430987
[TBL] [Abstract][Full Text] [Related]
51. Glucagon secretion and its association with glycaemic control and ketogenesis during sodium-glucose cotransporter 2 inhibition by ipragliflozin in people with type 1 diabetes: Results from the multicentre, open-label, prospective study.
Nakamura Y; Horie I; Kitamura T; Kusunoki Y; Nishida K; Yamamoto A; Hirota Y; Fukui T; Maeda Y; Minami M; Matsui T; Kawakami A; Abiru N
Diabetes Obes Metab; 2024 May; 26(5):1605-1614. PubMed ID: 38253809
[TBL] [Abstract][Full Text] [Related]
52. Sodium-glucose cotransporter 2 inhibition normalizes glucose metabolism and suppresses oxidative stress in the kidneys of diabetic mice.
Tanaka S; Sugiura Y; Saito H; Sugahara M; Higashijima Y; Yamaguchi J; Inagi R; Suematsu M; Nangaku M; Tanaka T
Kidney Int; 2018 Nov; 94(5):912-925. PubMed ID: 30021702
[TBL] [Abstract][Full Text] [Related]
53. Distinct Glucose-Lowering Mechanisms of Ipragliflozin Depending on Body Weight Changes.
Kutoh E; Murayama T; Wada A; Hirate M
Drugs R D; 2016 Dec; 16(4):369-376. PubMed ID: 27798769
[TBL] [Abstract][Full Text] [Related]
54. A sodium-glucose co-transporter 2 inhibitor empagliflozin prevents abnormality of circadian rhythm of blood pressure in salt-treated obese rats.
Takeshige Y; Fujisawa Y; Rahman A; Kittikulsuth W; Nakano D; Mori H; Masaki T; Ohmori K; Kohno M; Ogata H; Nishiyama A
Hypertens Res; 2016 Jun; 39(6):415-22. PubMed ID: 26818652
[TBL] [Abstract][Full Text] [Related]
55. The Role of SGLT2 Inhibitor Ipragliflozin on Cardiac Hypertrophy and microRNA Expression Profiles in a Non-diabetic Rat Model of Cardiomyopathy.
Takasu T
Biol Pharm Bull; 2022; 45(9):1321-1331. PubMed ID: 36047201
[TBL] [Abstract][Full Text] [Related]
56. Combination treatment with ipragliflozin and metformin: a randomized, double-blind, placebo-controlled study in patients with type 2 diabetes mellitus.
Veltkamp SA; van Dijk J; Collins C; van Bruijnsvoort M; Kadokura T; Smulders RA
Clin Ther; 2012 Aug; 34(8):1761-71. PubMed ID: 22795925
[TBL] [Abstract][Full Text] [Related]
57. Tolerability and Efficacy of Ipragliflozin in The Management of Inadequately Controlled Type 2 Diabetes mellitus: A Systematic Review and Meta-analysis.
Elgebaly A; Abdelazeim N; Abdelazeim B; El Ashal G; Mattar O; Namous L; Nasreldin N
Exp Clin Endocrinol Diabetes; 2021 Jan; 129(1):56-72. PubMed ID: 29913526
[TBL] [Abstract][Full Text] [Related]
58. Long-term treatment with the Na+-glucose cotransporter inhibitor T-1095 causes sustained improvement in hyperglycemia and prevents diabetic neuropathy in Goto-Kakizaki Rats.
Ueta K; Ishihara T; Matsumoto Y; Oku A; Nawano M; Fujita T; Saito A; Arakawa K
Life Sci; 2005 Apr; 76(23):2655-68. PubMed ID: 15792833
[TBL] [Abstract][Full Text] [Related]
59. [Visualization of mechanism of action, and a further therapeutic potential of ipragliflozin, a selective SGLT2 inhibitor].
Takasu T; Takakura S; Hamada K
Nihon Yakurigaku Zasshi; 2016; 148(5):266-271. PubMed ID: 27803440
[No Abstract] [Full Text] [Related]
60. Ipragliflozin and sitagliptin differentially affect lipid and apolipoprotein profiles in type 2 diabetes: the SUCRE study.
Nagao M; Sasaki J; Tanimura-Inagaki K; Sakuma I; Sugihara H; Oikawa S;
Cardiovasc Diabetol; 2024 Feb; 23(1):56. PubMed ID: 38331780
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
